Project Grant R01HL175985
Award Date 8/20/25
Completion Date 5/31/29
Dollars Obligated $630K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New Haven, CT 06519, USA
Similar Awards
- This $549,796 project grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI), which is part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research conducted by Cedars-Sinai Medical Center in West Hollywood, CA to investigate the mechanisms by which mutations in the TET2 and IDH2 genes associated with acute myeloid leukemia (AML) disrupt cardiac metabolism and lead to cardiomyopathy and heart...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $540,856 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF) on Dec 15, 2024. The goal of this 4-year project is to identify transcriptional regulators that control endocardial-specific gene expression and valve development, as well as understand the regulation and function of the SLC16A2 gene during heart injury and regeneration. The...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $694,252.00 to Cedars-Sinai Medical Center in California to investigate the mechanisms of cardioprotective Y RNA signaling in macrophages. The goal is to better understand how a small non-coding RNA called YREX3 can enhance the ability of macrophages to clear dead cells and promote cardiac tissue healing after a myocardial...
- This $834,249 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a comparative study of clinical outcomes, patient experiences, and mechanistic insights between transcatheter and surgical treatment of degenerative mitral regurgitation (DMR). The study aims to provide long-term data on clinical effectiveness, safety, and patient-reported outcomes to inform treatment selection and guide patient care. It will also utilize...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Cedars-Sinai Medical Center in West Hollywood, CA provides $248,999.00 in funding from September 1, 2025 through August 31, 2028. The project aims to characterize the cellular components of the hematopoietic stem cell (HSC) niche in the liver during extramedullary hematopoiesis, identify HSC clones initiating liver extramedullary hematopoiesis, and investigate the role of...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $134,998 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the J. David Gladstone Institutes in San Francisco, CA. The grant, awarded on July 20, 2025, will support research to define the cellular and molecular mechanisms driving the formation of the linear heart tube during embryonic development. The primary objectives are to: 1) quantitatively analyze cell movements and behaviors required for proper...
- The National Heart Lung and Blood Institute (NHLBI), a civilian agency within the U.S. government, awarded a $683,048 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Research Institute at Nationwide Children's Hospital. The purpose of this 5-year project grant, with a start date of May 1, 2025 and a completion date of March 31, 2030, is to investigate the cellular and molecular mechanisms by which the zinc ion importer ZIP8 impacts the formation of the...
- The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $126,309 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Children's Hospital Medical Center in Cincinnati, Ohio. This 2-year research project, awarded on June 16, 2025, aims to characterize the functional role of a novel cardiac and adipose-enriched microprotein called NRAC and its involvement in lipid droplet biogenesis and lipid metabolism within the cardiovascular system. The research will...
- This $568,177 federal Project Grant award, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on how centrioles, the core structures of centrosomes, control mammalian development. The University of California, San Francisco (UCSF) is the primary awardee and will leverage advanced techniques like centrosome affinity capture mass spectrometry and pan-expansion microscopy to investigate how centriole defects...
- The Cedars-Sinai Medical Center was awarded a $759,206 Project Grant by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to conduct research on a combination therapy using hydrogen sulfide (H2S) and glucagon-like peptide-1 (GLP-1) agonists to treat heart failure with preserved ejection fraction (HFpEF). The research aims to determine if this combination therapy can synergistically improve cardiovascular outcomes in patients with cardiometabolic HFpEF...